

| | | | |
|--|--|----------------------------------|--------------------------|
| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,935 |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | Applicant Donald E. Staunton | |
| | | Filing Date 10/12/01 | Group 1646 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|--------------------|------------|------|-------|----------|-------------------------------|
| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date if Appropriate |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--|-----------------|------------------|---------|-------|----------|-------------|
| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | | | | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
|--|--|---|--|--|--|--|--|
| JB | | Xiong <i>et al.</i> , "An Isoleucine-based Allosteric Switch Controls Affinity and Shape Shifting in Integrin CD11b A-domain," <i>JBC Papers in Press</i> , (October 16, 2000). | | | | | |
| | | J. Biol. Chem. Vol. 275 Pages 38762-38767 (2000) | | | | | |
| | | | | | | | |

RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

| | |
|--|---|
| EXAMINER <i>JB. Brown</i> | DATE CONSIDERED <i>12 September 2001</i> |
| *EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



| | | | |
|--|--|----------------------------------|----------------------------------|
| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,935 |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | Applicant Donald E. Staunton | |
| | | Filing Date 10/12/01 | Group 1646 1631 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|--------------------|------------|------|-------|----------|-------------------------------|
| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date if Appropriate |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

RECEIVED
DEC 10 2002
TECH CENTER 1600/2900

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--|-----------------|------------------|---------|-------|----------|-------------|
| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | | | | | | | |
| | | | | | | | |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|-----|-----|--|
| JBS | C61 | Jones <i>et al.</i> , "Ligand occupancy of the $\alpha V\beta 3$ integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 93:2482-2487 (March, 1996) |
| JBS | C62 | Lu <i>et al.</i> , "An isolated, surface-expressed I domain of the integrin $\alpha L\beta 2$ is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 98(5):2387-2392 (February 27, 2001) |
| JBS | C63 | Nolte <i>et al.</i> , "Crystal structure of the $\alpha 1\beta 1$ integrin I-domain: insights into integrin I-domain function," <i>FEBS Letters</i> , 452:379-385 (1999) |
| | | |
| | | |
| | | |
| | | |

| | |
|---|--|
| EXAMINER <i>JBS. Bursica</i> | DATE CONSIDERED <i>2 September 2004</i> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



Sheet 1 of 5

RECEIVED

| | | | |
|----------------------------------|--|----------------------------------|------------------------|
| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,9 |
| INFORMATION DISCLOSURE STATEMENT | | Applicant Donald E. Staunton | |
| | | Filing Date 10/12/01 | Group 1646 1631 |

TECH CENTER 1600 2900

AUG 27 2002

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------------|------------------------|-------|----------|----------------------------|
| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date if Appropriate |
| JLB | A1 | 5,847,088 | 12/08/98 | Cousens <i>et al.</i> | 530 | 388.1 | |
| JLB | A2 | 5,888,809 | 03/30/99 | Allison | 435 | 325 | |
| JLB | A3 | 6,251,395 | 06/26/01 | Gallatin <i>et al.</i> | 424 | 144.1 | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--|-----------------|------------------|---------|-------|----------|-------------|----|
| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| | | | | | | | | |
| | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|----|--|
| JLB | C1 | Aghazdeh <i>et al.</i> , "Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation," <i>Cell</i> , 102:625-633 (Sept. 1, 2000) |
| JLB | C2 | Amyes <i>et al.</i> , "Trimethoprim-Sensitivity Testing and Thymineless Mutants," <i>J. Med. Microbiol.</i> , 7(2):143-153 (1974) |
| JLB | C3 | Andersen <i>et al.</i> , "Protein export and drug efflux through bacterial channel-tunnels," <i>Curr. Opin. Cell Biol.</i> , 13:412-416 (2001) |
| JLB | C4 | Ausubel <i>et al.</i> , "Enzymatic Amplification of DNA by PCR: Standard Procedures and Optimization," <i>Curr. Protocols Mol. Biol.</i> , 3:15.1.1-15.1.14 (2001) |
| JLB | C5 | Baldock <i>et al.</i> , "A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase," <i>Science</i> , 274:2107-2110 (Dec. 20, 1996) |
| JLB | C6 | Berge <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharmaceutical Sciences</i> , 66(1):1-19 (Jan., 1977) |
| JLB | C7 | Bollag <i>et al.</i> , "Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action" <i>Cancer Research</i> , 55:2325-2333 (June 1, 1995) |

| | |
|---|--------------------------------------|
| EXAMINER JLB | DATE CONSIDERED 17 September 2004 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



| | | | | |
|---|--|--|----------------------------------|--------------------------|
| m PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,993 |
| INFORMATION DISCLOSURE STATEMENT | | | Applicant Donald E. Staunton | |
| | | | Filing Date 10/12/01 | Group 1646 |

1631

AUG 27 2002

TECH CENTER 1600/2900

RECEIVED

| | | |
|----|-----|--|
| JB | C8 | Briesewitz <i>et al.</i> , "Expression of Native and Truncated Forms of the Human Integrin α_1 Subunit," <i>J. Biol. Chem.</i> , 268(4):2989-2996 (February 5, 1993) |
| JB | C9 | Chang <i>et al.</i> , "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 91:11408-11412 (November, 1994) |
| JB | C10 | Copley <i>et al.</i> , "Protein families in multicellular organisms," <i>Curr. Opin. Struct. Biol.</i> , 9:408-415 (1999) |
| JB | C11 | Couzin, "Integrin Crystal Structure Solved," <i>Science</i> , 293:1743-1746 (September 7, 2001) |
| JB | C12 | Cranmer <i>et al.</i> , "Glycoprotein (GP) Ib-IX-transfected Cells Roll on a von Willebrand Factor Matrix under Flow," <i>J. Biol. Chem.</i> , 274(10):6097-6106 (March 5, 1999) |
| JB | C13 | Crompton <i>et al.</i> , "Regulation of Tiam1 Nucleotide Exchange Activity by Pleckstrin Domain Binding Ligands," <i>J. Biol. Chem.</i> , 275(33):25751-25759 (August 18, 2000) |
| JB | C14 | deFougerolles <i>et al.</i> , "Regulation of inflammation by collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ in models of hypersensitivity and arthritis," <i>J. Clin. Invest.</i> , 105(6):721-729 (March, 2000) |
| JB | C15 | De Vos <i>et al.</i> , "Three-Dimensional Structure of an Oncogene Protein: Catalytic Domain of Human c-H-ras p21," <i>Science</i> , 239:888-893 (February 19, 1988) |
| JB | C16 | Diamond <i>et al.</i> , "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1(CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Biology</i> , 120(4):1031-1043 (February, 1993) |
| JB | C17 | Dickeson <i>et al.</i> , "Ligand recognition by the I domain-containing integrins," <i>Cell. Mol. Life Sci.</i> , 54:556-566 (1998) |
| JB | C18 | Didsbury <i>et al.</i> , "rac, a Novel ras-related Family of Proteins That Are Botulinum Toxin Substrates," <i>J. Biol. Chem.</i> , 264(28):16378-16382 (October 5, 1989) |
| JB | C19 | Edwards <i>et al.</i> , "The protein fold of the von Willebrand factor type A domain is predicted to be similar to the open twisted β -sheet flanked by α -helices found in human ras-p21," <i>FEBS Letter</i> , 358:283-286 (1995) |
| JB | C20 | Eliopoulos <i>et al.</i> , "Antimicrobial Combinations," in <i>Antibiotics in Laboratory Medicine</i> , 4 th Ed., pp. 330-396, (V. Lorian, ed., 1996) |
| JB | C21 | Emsley <i>et al.</i> , "Crystal Structure of the I Domain from Integrin $\alpha 2\beta 1$," <i>J. Biol. Chem.</i> , 272(45):28512-28517 (November 7, 1997) |
| JB | C22 | Emsley <i>et al.</i> , "Structural Basis of Collagen Recognition by Integrin $\alpha 2\beta 1$," <i>Cell</i> , 101:47-56 (March 31, 2000) |

| | |
|---|--------------------------------------|
| EXAMINER JB. Bures | DATE CONSIDERED 17 September 2004 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |




RECEIVED
AUG 27 2002
SHEET 5 of 5
TECH CENTER 1600 2900

| | | | |
|----------------------------------|--|----------------------------------|----------------------------------|
| in PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,9 |
| INFORMATION DISCLOSURE STATEMENT | | Applicant Donald E. Staunton | |
| | | Filing Date 10/12/01 | Group 1646 1631 |

| | | |
|----|-----|---|
| JB | C23 | Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Curr. Opin. Struct. Biol.</i> , 6:377-385 (1996) |
| JB | C24 | Hahn <i>et al.</i> , "The complete sequences of plasmids pFNeo and pMN-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines," <i>Gene</i> , 127:267-268 (1993) |
| JB | C25 | Hardma <i>et al.</i> , eds., "Pharmacokinetics," Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, New York, New York, McGraw-Hill, Chapter 1, pp. 11-16 (1996) |
| JB | C26 | Higuchi <i>et al.</i> , eds., "Prodrug as Novel Drug Delivery Systems, ACS Symposium Series, 14, table of contents only (1975) |
| JB | C27 | Higuchi, "Prodrug and Drug Delivery - An Overview," Bioreversible Carriers in Drug Design Theory and Application, Roche ed., Pergamon Press, Chapter 1, pp. 1-12, (1987) |
| JB | C28 | Hitchings and Baccanari, "Design and Synthesis of Folate Antagonists as Antimicrobial Agents", in <i>Folate Antagonists as Therapeutic Agents</i> , Chapter 4, Vol. 1:151-172 (1984) |
| JB | C29 | Hua Jing <i>et al.</i> , "New structural motifs on the chymotrypsin fold and their potential roles in complement factor B," <i>EMBO J.</i> , 19(2):164-173 (2000) |
| JB | C30 | Huth <i>et al.</i> , "NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(10):5231-5236 (May 9, 2000) |
| JB | C31 | Kirshenbaum <i>et al.</i> , "Predicting allosteric switches in myosins," <i>Protein Science</i> , 8:1806-1815 (1999) |
| JB | C32 | Lee <i>et al.</i> , "Crystal Structure of the A Domain from the α Subunit of Integrin CR3 (CD11b/CD18)," <i>Cell</i> , 80:631-638 (February 24, 1995) |
| JB | C33 | Lochter <i>et al.</i> , " $\alpha 1$ and $\alpha 2$ Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression," <i>Mol. Biol. Cell</i> , 10:271-282 (February, 1999) |
| JB | C34 | Madej <i>et al.</i> , "Threading a Database of Protein Cores," <i>Proteins: Structure, Functions and Genetics</i> , 23:356-369 (1995) |
| JB | C35 | Mandell <i>et al.</i> , "Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections," in <i>The Pharmacological Basis of Therapeutics</i> Chapter 44, Antimicrobial Agents, 1057-1072 (Goodman and Gilman eds., 1996) |
| JB | C36 | Nelson <i>et al.</i> , "Matrix Metalloproteinases: Biologic Activity and Clinical Implications," <i>J. Clin. Oncol.</i> , 18(5):1135-1149 (March, 2000) |

| | |
|--|--------------------------------------|
| EXAMINER J.B. Bussan | DATE CONSIDERED 17 September 2004 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. | |



For PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

27866/36470A

Serial No.

09/976835

Applicant

Donald E. Staunton

Filing Date

10/12/01

Group

1646

INFORMATION DISCLOSURE STATEMENT

163/

TECH CENTER 1600/2900

AUG 27 2002

RECEIVED

| | | |
|----|-----|--|
| JB | C37 | Nobes, "Rho GTPases and Cell Migration-Fibroblast Wound Healing," <i>Meth. Enzymol.</i> , 325:441-449 (2000) |
| JB | C38 | Nogales <i>et al.</i> , "Tubulin and FtsZ form a distinct family of GTPases," <i>Nature Structural Biology</i> , 5(6):451-458 (June, 1998) |
| JB | C39 | Oxvig <i>et al.</i> , "Conformational changes in tertiary structure near the ligand binding site of an integrin I domain," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 96:2215-2220 (March, 1999) |
| JB | C40 | Pozzi <i>et al.</i> , "Elevated matrix metalloprotease and angiostatin levels in integrin $\alpha 1$ knockout mice cause reduced tumor vascularization," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(5):2202-2207 (February 29, 2000) |
| JB | C41 | Ponting <i>et al.</i> , "SMART: identification and annotation of domains from signalling and extracellular protein sequences," <i>Nucl. Acids Res.</i> , 27(1):226-229 (1999) |
| JB | C42 | Poste <i>et al.</i> , "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Vol. XIV, Academic Press, New York, New York, Prescott, ed., Chapter 4, pp. 33-71 (1976) |
| JB | C43 | Qu <i>et al.</i> , "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin," <i>Structure</i> , 4:931-942 (August 15, 1996) |
| JB | C44 | Rich <i>et al.</i> , "Trench-shaped Binding Sites promote Multiple Classes of Interactions between Collagen and the Adherence Receptors, $\alpha_1\beta_1$ Integrin and <i>Staphylococcus aureus</i> Can MSCRAMM," <i>J. Biol. Chem.</i> , 274(35):24906-24913 (August 27, 1999) |
| JB | C45 | Richey <i>et al.</i> , "The Biosynthesis of Folic Acid," <i>J. Biol. Chem.</i> , 244(6):1582-1592 (March 25, 1969) |
| JB | C46 | Rossmann <i>et al.</i> , "Bacterial Expressed DH and DH/PH Domains," <i>Meth. Enzymol.</i> , 325:25-38 (2000) |
| JB | C47 | Rost, "PHD: Predicting One-Dimensional Protein Structure by Profile-Based Neural Networks," <i>Meth. Enzymol.</i> , 266:525-539 (1996) |
| JB | C48 | Sadhu <i>et al.</i> , "LFA-1 Binding Site in ICAM-3 Contains a Conserved Motif and Non-Cotniguous Amino Acids," <i>Cell Adhes. Commun.</i> , 2:429-440 (1994) |
| JB | C49 | Scita <i>et al.</i> , "Signaling from Ras to Rac and beyond: not just a matter of GEFs," <i>EMBO J.</i> , 19(11):2393-2398 (2000) |
| JB | C50 | Schultz <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 95:5857-5864 (May, 1998) |
| JB | C51 | Schultz <i>et al.</i> , "SMART: a web-based tool for the study of genetically mobile domains," <i>Nucl. Acids Res.</i> , 28(1):231-234 (2000) |
| JB | C52 | Self <i>et al.</i> , "Purification of Recombinant Rho/Rac/G25K from <i>Escherichia coli</i> ," <i>Meth. Enzymol.</i> , 256:3-10 (1995) |


EXAMINER

JLB. Brown

DATE CONSIDERED

17 September 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 5

TECH CENTER 1600/2900

AUG 27 2002

RECEIVED

| | | | |
|----------------------------------|--|----------------------------------|----------------------------------|
| For m...O-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27866/36470A | Serial No. 09/976,... |
| INFORMATION DISCLOSURE STATEMENT | | Applicant Donald E. Staunton | |
| | | Filing Date 10/12/01 | Group 1646 1631 |

| | | |
|----|-----|---|
| JB | C53 | Shi <i>et al.</i> , "Bisubstrate Analogue Inhibitors of 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase: Synthesis and Biochemical and Crystallographic Studies," <i>J. Med. Chem.</i> , 44:1364-1371 (2001) |
| JB | C54 | Symons, "The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies," <i>Curr. Opin. in Biotech.</i> , 6:668-674 (1995) |
| JB | C55 | John Wiley & Sons, Inc., "Classical Pathway Evaluation," Current Protocols in Immunology, Coligan <i>et al.</i> , eds. Vol. 3, Chapter 13, Unit 13.1 (2000) |
| JB | C56 | Velling <i>et al.</i> , "cDNA Cloning and Chromosomal Localization of Human α_{11} Integrin," <i>J. Biol. Chem.</i> , 274(36):25735-25742 (September 3, 1999) |
| JB | C57 | Worthylake <i>et al.</i> , "Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1," <i>Nature</i> , 408:682-688 (December 7, 2000) |
| JB | C58 | Young <i>et al.</i> , "Predicting conformational switches in proteins," <i>Protein Science</i> , 8:1752-1764 (1999) |
| JB | C59 | Yu <i>et al.</i> , "Ca ²⁺ -mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks <i>in vitro</i> ," <i>EMBO J.</i> , 16(17):5455-5463 (1997) |
| JB | C60 | "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, <i>National Committee Clinical Laboratory Standards Guidelines</i> , - 5 th Ed., Vol. 20, No. 2, pp. 1-27, Wayne, PA (January, 2000) |

| | |
|--|---|
| EXAMINER <i>J.B. B...</i> | DATE CONSIDERED <i>17 September 2004</i> |
| *EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |